Record 9328 View: Standard | Glossary HistCite Guide |
Author(s): Kanzawa T; Germano IM; Komata T; Ito H; Kondo Y; Kondo S
Title: Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells
Source: CELL DEATH AND DIFFERENTIATION 11 (4): 448-457
Date: 2004 APR
Document Type: Journal : Article
DOI: 10.1038/sj.cdd.4401359
Language: English
Comment:
Address: Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA.
CUNY Mt Sinai Sch Med, Dept Neurosurg, New York, NY 10029 USA. Reprint: Kondo, S, Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, 1515
Holcombe Blvd,Unit 64, Houston, TX 77030 USA. E-mail: seikondo@mdanderson.org
Author Keywords: temozolomide; malignant glioma; autophagy; apoptosis; LC3
KeyWords Plus: PHASE-II TRIAL; GENE PROMOTER; DEATH; INHIBITORS; APOPTOSIS; KINASE;
MACROAUTOPHAGY; EXPRESSION; INDUCTION; RADIATION
Abstract: Autophagy is originally named as a process of protein recycling. It begins with sequestering cytoplasmic organelles in a membrane vacuole called autophagosome. Autophagosomes then fuse with lysosomes, where the materials inside are degraded and recycled. To date, however, little is known about the role of autophagy in cancer therapy. In this study, we present that temozolomide ( TMZ), a new alkylating agent, inhibited the viability of malignant glioma cells in a dose-dependent manner and induced G2/M arrest. At a clinically achievable dose (100 muM), TMZ induced autophagy, but not apoptosis in malignant glioma cells. After the treatment with TMZ, microtubule-associated protein light-chain 3 (LC3), a mammalian homologue of Apg8p/Aut7p essential for amino-acid starvation-induced autophagy in yeast, was recruited on autophagosome membranes. When autophagy was prevented at an early stage by 3-methyladenine, a phosphatidylinositol 3-phosphate kinase inhibitor, not only the characteristic pattern of LC3 localization, but also the antitumor effect of TMZ was suppressed. On the other hand, bafilomycin A1, a specific inhibitor of vacuolar type H+-ATPase, that prevents autophagy at a late stage by inhibiting fusion between autophagosomes and lysosomes, sensitized tumor cells to TMZ by inducing apoptosis through activation of caspase-3 with mitochondrial and lysosomal membrane permeabilization, while LC3 localization pattern stayed the same. These results indicate that TMZ induces autophagy in malignant glioma cells. Application of an autophagy inhibitor that works after the association of LC3 with autophagosome membrane, such as bafilomycin A1, is expected to enhance the cytotoxicity of TMZ for malignant gliomas.
Cited References: AGARWALA SS, 2000, ONCOLOGIST, V5, P144 ALTAN N, 1998, J EXP MED, V187, P1583 ARICO S, 2001, J BIOL CHEM, V276, P35243 AVGEROPOULOS NG, 1999, ONCOLOGIST, V4, P209 BLOMMAART EFC, 1997, EUR J BIOCHEM, V243, P240 BOWER M, 1997, CANCER CHEMOTH PHARM, V40, P484 BOYA P, 2003, ONCOGENE, V22, P3927, DOI 10.1038/sj.onc.1206622 BRUICK RK, 2000, P NATL ACAD SCI USA, V97, P9082 BURSCH W, 1996, CARCINOGENESIS, V17, P1595 BURSCH W, 2000, ANN NY ACAD SCI, V926, P1 BURSCH W, 2000, J CELL SCI, V113, P1189 DATRI S, 1995, ANN ONCOL, V6, P389 DATRI S, 1998, MOL PHARMACOL, V54, P334 DECAMILLI P, 1996, SCIENCE, V271, P1533 DENNY BJ, 1994, BIOCHEMISTRY-US, V33, P9045 FRIEDMAN HS, 2000, CLIN CANCER RES, V6, P2585 HIROSE Y, 2001, CANCER RES, V61, P1957 KABEYA Y, 2000, EMBO J, V19, P5720 KANZAWA T, 2003, CANCER RES, V63, P2103 KIM J, 2000, ANNU REV BIOCHEM, V69, P303 KLIONSKY DT, 1999, ANNU REV CELL DEV BI, V15, P1 KOGA S, 2000, HUM GENE THER, V11, P1397 KOMATA T, 2000, GENE THER, V7, P2071 KOMATA T, 2001, CANCER RES, V61, P5796 KONDO K, 1995, J CHEM SOC CHEM 0107, P55 LIANG XH, 1999, NATURE, V402, P672 MAHALEY MS, 1989, J NEUROSURG, V71, P826 MANABE T, 1993, J CELL PHYSIOL, V157, P445 MIZUSHIMA N, 2001, J CELL BIOL, V152, P657 MUNAFO DB, 2001, J CELL SCI, V114, P3619 NARA A, 2002, CELL STRUCT FUNCT, V27, P29 NEWLANDS ES, 1997, CANCER TREAT REV, V23, P35 OGIERDENIS E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0 PAGLIN S, 2001, CANCER RES, V61, P439 PETIOT A, 2000, J BIOL CHEM, V275, P992 SEGLEN PO, 1992, EXPERIENTIA, V48, P158 STEVENS MFG, 1984, J MED CHEM, V27, P196 TOKER A, 1997, NATURE, V387, P673 VANHAESEBROECK B, 1997, TRENDS BIOCHEM SCI, V22, P267 YAMAMOTO A, 1998, CELL STRUCT FUNCT, V23, P33 YAO KC, 2003, J NEUROSURG, V98, P378 YUNG WKA, 1999, J CLIN ONCOL, V17, P2762 |